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Background: Currently no tools to predict risk of acute (AP) and recurrent pancreatitis (ARP) in children with cystic ﬁbrosis (CF) are available. We
assessed the prevalence of AP/ARP and tested the potential role of Pancreatic Insufﬁciency Prevalence (PIP) score in a cohort of children with CF.
Methods: We identiﬁed two groups of children, on the basis of presence/absence of AP/ARP, who were compared for age at diagnosis, clinical
features, genotypes and sweat chloride level. PIP score was calculated for each patient.
Results: 10/167 (5.9%) experienced at least one episode of AP during follow up; 10/10 were pancreatic sufﬁcient (PS). Patients with AP/ARP showed a
PIP score ≤0.25 more frequently (6/10) than patients without AP/ARP. The odds ratio (95% CI) of developing pancreatitis was 4.54 (1.22–16.92) for
patients with PIP b0.25 when compared with those who have a PIP score N0.25 (p 0.0151). PIP score was correlated with sweat chloride test (p b 0.01).
Conclusion: PIP score, PS status and normal/borderline sweat chloride levels could be applied to predict pancreatitis development in children with
CF. ARP could lead to pancreatic insufﬁciency.
© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: PIP score; Pancreatitis; Children; Cystic ﬁbrosis1. Introduction
Cystic fibrosis (CF) is the most common life-limiting
autosomal recessive disease of the Caucasian population, with
an incidence of approximately 1 in every 3000 live births
worldwide [1,2]. At present over 1900 mutations occur in the
CFTR gene that encodes for a cAMP-regulated chloride
channel. CF phenotype includes multiorgan involvement with
predominant progressive respiratory disease, pancreatic insuf-
ficiency (PI) and male infertility [1,3,4]. Pancreatic status is
generally related to severity of CFTR dysfunction [5,6]; as a
rule PS occurs in patients carrying at least a “mild” mutation on
one allele [5,6].⁎ Corresponding author at: Department of Translational Medical Sciences
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.lishedRecent findings have shown a wide disease heterogeneity
associated with different CFTR gene class mutations. About
10% of patients show non-classic CF disease including mono
or oligo-symptomatic phenotype, pancreatic sufficiency (PS)
and normal/borderline sweat test [5,7].
The prevalence of pancreatitis in CF patients is higher than
in general population. Due either to residual pancreatic acinar
tissue and influence of modifier genes PS patients have a higher
risk of symptomatic pancreatitis up to 20%, when compared
with patients with CF and PI [7–11].
Acute pancreatitis (AP), as recently defined by Morinville et
al. [12], is an emerging problem in pediatric population with an
increasing incidence as reported in several studies (3.6–13.2
cases per 100,000 children) [13,14]. No evidence-based
guidelines are currently available regarding diagnostic, natural
history and treatment aspects of children with AP [12].
Etiologies of pancreatitis in children are markedly different
from adults involving biliary disease, drug-induced pancreatitis,by Elsevier B.V. All rights reserved.
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However, up to 30% of cases remain with no defined etiology [12].
A CFTR “mild” mutation on at least one allele accounts for
the residual pancreatic function; the resulting decreased ductal
bicarbonate secretion predisposes to acidification of the
pancreatic lumen and activation of proteolytic enzymes [10].
In CF patients with PS a residual pancreatic reserve can avoid
abnormal nutrient digestion, but it may contribute to pancre-
atitis, due also to genetic and environmental factors. In time,
recurrence of symptomatic AP may induce fibrosis and
destruction of exocrine/endocrine parenchyma, leading to
progression from PS to PI [15]. In CF pancreatitis is diagnosed
by symptoms, such as abdominal pain associated with varying
degrees of nausea and vomiting, increasing value of serum
pancreatic enzyme concentrations with a variation in the agreed
“cut-off” limit, and imaging evidences of acute inflammation of
the pancreas [12,15]. However, in some cases these findings
cannot be detected and asymptomatic AP could remain an
under-recognized condition. In children, treatment is based
only on symptomatic approaches with no evidence-based
guidelines [12]. Few data are available for controlling and
preventing acute recurrent pancreatitis (ARP); the role of lower
fat intake in the diet is only partially successful. In 2011, Ooi et
al. [11] introduced a new surrogate measure known as the
Pancreatic Insufficiency Prevalence (PIP) score. By PIP score,
a relationship between the functional severity of CFTR
genotype and risk of pancreatitis was observed among patients
with CF and PS [10,11]. On the basis of the PIP score
value, mutations were classified as either mild (≤0.25) or
moderate-severe (≥0.25) [11]: a higher PIP score is generally
associated to PI–CF phenotype and a lower risk of pancreatitis,
while a lower PIP score is associated with the PS–CF
phenotype and a higher risk of pancreatitis.
The aims of our study were:1) to evaluate retrospectively the
prevalence of pancreatitis in a cohort of children with CF; 2) to
correlate this prevalence to pancreatic status, CFTR gene
mutations and sweat chloride level; and 3) to test the potential
role of PIP score as a tool to predict risk of pancreatitis in
children with CF and rare mutations.2. Methods
185 pediatric CF patients [median age ± standard deviation
(SD): 11.4 ± 5.3, range 1.1–18 years] were evaluated for
recruitment in the study. 18/185 (9.7%) were ruled out since
CFTR analysis failed to identify mutations on both alleles and
PIP score could not be determined. We examined 167 patients
with CF (79 males, median age ± SD 11.8 ± 5.9, range 1.3–
18 years) in regular follow up at the CF Regional Care Centre
of Naples, Italy. CF diagnosis was based on suggestive clinical
symptoms, quantitative pilocarpine iontophoretic sweat chlo-
ride concentrations over 60 mmol/l and/or identified CFTR
mutations on both alleles, according to the current consensus
reports [5,16]. The analysis of all CFTR coding regions (27
exons and intron–exon boundaries) was performed by gene
sequencing (detection rate 94%).A record of demographic, genetic and biochemical data
regarding all our CF patients is regularly available in a
computerized database in our Care Center. All medical records
of patients in follow-up from December 2002 to December
2012 were retrospectively evaluated for the study. Status of PS
was defined on the basis of fecal pancreatic elastase higher than
200 mcg/g [17,18] measured outside of AP.
Episodes of AP and ARP were extracted from database in
order to define their prevalence. On the basis of presence/
absence of AP/ARP we identified two groups of patients who
were compared for age at CF diagnosis, clinical features,
genotypes and sweat chloride level.
AP was defined as requiring at least 2 of the following
criteria: abdominal pain compatible with pancreatitis (with no
other attributable cause), serum amylase and/or lipase values
≥3 folds higher than the upper limit of the reference range,
imaging evidence of acute (such as pancreatic edema,
hemorrhage, or necrosis) or chronic pancreatitis (such as
calcification or characteristic ductal changes), as previously
described [12]. Episodes of pancreatitis concerning other
etiologies were ruled out.
Clinical data were scheduled as age of onset and number of
pancreatitis, during the observation period, pancreatitis risk factors
such as drugs, acute infections, complications as pseudocyst,
abscess, retroperitoneal hemorrhage and hypocalcemic tetany, as
well as imaging evidences by ultrasonography, computerized
tomography, or endoscopic retrograde cholangiopancreatography,
detected during episodes of pancreatitis.
Patients with PS phenotype were monitored to detect a
progression to PI, once a year or more when suggestive symptoms
occurred.2.1. Pancreatic Insufficiency Prevalence (PIP) score
PIP score has been recently developed and validated [11]. It
was based on the prevalence of PI in a large and well-defined
cohort of CF patients. We calculated PIP score for each mutation
as ratio between PI patients carrying a single mutation and all PI
and PS patients carrying the same mutation both in a homozygous
state and in a heterozygous state compoundwith mutations known
to have severe consequences. Data were compared with those
of Ooi et al. [11,12]. We considered CF mutation as mild when
PIP score was ≤0.25 and moderate-severe when PIP score was
N0.25, according to the cut-off value suggested by the Canadian
Consortium for CF Genetic Studies (CCCFGS) [11].
Subsequently we estimated the PIP score of each enrolled
patients.2.2. Statistics
Data with a Gaussian distribution were compared by an
independent Student t test, Pearson analysis was used to
evaluate correlation between factors, while Chi-Square test was
used for non-normal data. Level of significance was set at
p b 0.05. Data analysis was performed using SPSS software
(17.0).
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3.1. Clinical characteristics
A flow-chart of enrolled study population was shown in Fig. 1.
10/167 children (5.9%) experienced at least one episode of AP
during the observational period. 54/167 (32.3%) patients were
classified as PS. All patients with pancreatitis were PS (10/54
[18.5%]). In the PS group CF diagnosis was generally performed
later than patients with PI (median age ± SD: 3.0 ± 5.1 vs.
1.19 ± 2.12 respectively; p b 0.05). Symptoms at diagnosis were
respiratory acute disease in 23, AP or ARP in 4, recurrent
abdominal pain in 2, hyponatriemic dehydration in 3, failure to
thrive in 2 and nasal polyposis in one; 9 patients were diagnosed
by newborn screening (NBS) and 10 for familiarity. 38/54 PS
children (70.3%) had normal or borderline sweat chloride level.
As expected, mean sweat-chloride levels were lower in PS than in
PI patients (M ± SD: 46.2 ± 31.4 vs. 96.0 ± 13.6 respectively;
p b 0.001).
Among studied patients genetic analysis showed: 40/167
(24%) F508del/F508del, 63/167 (34%) F508del/other and 64/167
(38%) other/other. Two out of 167 enrolled patients were
compound heterozygous for I148T (F508del/I148T; G85E/
I148T). CF diagnosis was based on suggestive clinical symptoms,
sweat chloride levels N 60 mmol/l (85 and 114 mmol/l respec-
tively) and PI (fecal elastase b 100 mcg/g). Complex alleles were
ruled out.
Episodes of pancreatitis were detected at a mean age of
5.2 years (range 1–12.7 years). None of our patients showed
complications during the follow up (7.8 years, range 1.1–15.8)
but 1/10 developed PI 6.5 years later than the first episode of
AP. Patients with pancreatitis had a sweat chloride mean level
lower than patients without pancreatitis (M ± SD: 50.0 ± 34.5
vs. 81.8 ± 30.3; p b 0.05).Fig. 1. Study pClinical characteristics of patients with CF and pancreatitis
are shown in Table 1.
3.2. PIP score results
Table 2 shows PIP score results compared with those of Ooi
et al. Based on PIP score we divided patients into two groups:
122 out of 167 (73%) had a PIP score N0.25 [9/122 (7.3%) with
PS and 113/122 with PI], while 45 out of 167 (27%) had a PIP
score b0.25 (45/45 with PS). Among patients with PIP score
N0.25 only 2/122 (1.6%) patients had normal or borderline
sweat chloride test, while 38/45 (84.4%) with PIP score b0.25
showed a normal or borderline sweat chloride test with a
significant statistical difference (p b 0.001), as shown in
Table 3. Despite that the two groups were not comparable for
sample size, we registered that patients with pancreatitis had a
PIP score lower than patients without pancreatitis [M ± SD:
0.31 ± 0.41 vs. 0.66 ± 0.39; p b 0.001]; moreover the number
of patients with PANC was higher among those with PIP score
b0.25 when compared with those with PIP score N0.25 [6/10
(60%) vs. 39/157 (24.8%)]. The odds ratio (95% CI) of
developing pancreatitis was 4.54 (1.22–16.92) for patients with
PIP b0.25 when compared with those who have a PIP score
N0.25 (p 0.0151). A significant correlation between PIP score
and sweat chloride levels (Pearson correlation 0.829, p value
b0.001) (Fig. 2) was observed.
4. Discussion
In the last years an increasing percentage of patients with CF
have been described as having non-classic forms of CF [8].
These cases are generally characterized by a later onset of
symptoms such as pancreatitis, disseminated bronchiectasis,
congenital bilateral absence of vas deferens associated toopulation.
Table 1
PIP score for most frequent CFTR mutations in our cohort of patients.






G542X 17 17 1.00 0.99
CFTRdel2,3 3 3 1.00 1.00
1717-1G N A 3 3 1.00 0.95
R1066C 3 3 1.00 0.83
I148T 2 2 1.00 0.91
711 + 1G N T 2 2 1.00 1.00
R1158X 2 2 1.00 1.00
G1244E 2 2 1.00 N.D.
Y849X 2 2 1.00 N.D.
L732X 2 2 1.00 N.D.
17a-17b-18del 2 2 1.00 N.D.
E193X 2 2 1.00 1.00
N1303K 15 16 0.94 0.95
F508del 78 85 0.92 0.96
W1282X 8 9 0.88 0.95
2183AA N G 7 8 0.87 1.00
4016insT 4 5 0.80 1.00
G85E 4 6 0.67 0.73
D759G 2 3 0.66 0.00
G178R 2 3 0.66 0.00
3131del15 1 2 0.50 N.D.
2789 + 5G N A 1 2 0.50 0.38
(TG)12(T)5 0 8 0.00 N.D.
L977F 0 6 0.00 N.D.
D1152H 0 6 0.00 N.D.
V201M G/A 0 2 0.00 N.D.
3849 + 10kbC N T 0 2 0.00 0.09
R74W 0 2 0.00 N.D.
R117H 0 2 0.00 0.04
R334W 0 2 0.00 0.10
Abbreviations: PIP = Pancreatic Insufficiency Prevalence, PI = Pancreatic
Insufficiency, PS = Pancreatic Sufficiency.
Table 3
Relation between sweat test results and PIP score values.
Sweat test (Cl−) PIP score N 0.25 PIP score b 0.25
Normal b40 mmol/l 0 30
Borderline 40–60 mmol/l 2 8
Pathological N60 mmol/l 120 7
Abbreviations: PIP = Pancreatic Insufficiency Prevalence.
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CF-causing mutations with variability of CFTR protein
dysfunction. In this group an increasing percentage of patients
with CF and PS (about 27.5%) has been described [8]. We
suppose that both the increase of sensitivity of diagnostic
molecular tests for CF and early diagnosis by NBS have
contributed to detect non-classic CF disease.Table 2
Clinical characteristics of patients with CF and pancreatitis.




PI Age at first P
1 7 y P No 5 y/6 m
2 13 y P No 11 y
3 3 m FT, RTI No 1 y/6 m
4 10 m RAP No 2 y/3 m
5 10 y P No 8 y
6 8 m RTI, LD No to Yes 6 y
7 14 m P, RTI No 1 y
8 5 m MA, P No 3 y
9 2 m NS No 1 y/2 m
10 13 y P No 12 y/7 m
Abbreviations: CF = Cystic Fibrosis, P = pancreatitis, FT = failure to thrive, RTI =
MA = metabolic alkalosis, NS = newborn screening.A severe dysfunction of CFTR protein causes already in
utero, a progressive damage of acinar pancreatic tissue leading
to pancreatic acinar atrophy up to PI when N98% of pancreatic
parenchyma has been destroyed [8–11]. A residual function of
CFTR protein related to “mild” CFTR mutations could reduce
fluid pancreatic secretion and trypsinogen/trypsin wash-out
[19], preserving pancreatic enzymes secretion. Persistence of
normal residual acinar pancreatic tissue may favor pancreatitis.
This event has been previously reported as a relatively rare
finding (prevalence of 1.24%) [9] in all CF children.
Nevertheless, an increased incidence and prevalence of
non-classic CF, according to increasing median life expectancy,
may determine a higher prevalence (up to 14–17%) of
pancreatitis in adult CF patients with PS [7,8]. In all pediatric
patients in regular follow-up at our CF center we registered a
prevalence of PS of 29.1% (Fig. 1). Our data highlight a
prevalence of pancreatitis of 5.9% in CF children regardless of
pancreatic status and of 18.5% in PS subgroup, that is higher
than previously reported [9]. Moreover, according to Durno et
al. and Augarten at al. [7,8], all patients with pancreatitis were
PS.
We have applied the PIP score regardless of pancreatic
status in order to verify whether PIP score may help to early
predict the risk of pancreatitis, also in children diagnosed by
NBS. We found that a lower PIP score may predict the risk of
pancreatitis, confirming that more frequently a mild mutation
may predispose to pancreatitis. In particular, patients with a PIP
score ≤0.25 had pancreatitis and at least a mild mutation on
one allele more frequently than patients with PIP score N0.25
without pancreatitis and a moderate-severe mutation (60.0% vs.
24.8%, respectively).
Moreover, in our cohort of patients we found a significant
correlation between values of PIP score and sweat chlorideNo. of P Genotype Sweat chloride
value (mmol/l)
PIP score
N2 E193X/L997F 24 0
N2 G542X/L997F 22 0
N2 3849 + 10kbC- N T/G1244E 27 0.09
N2 2183AA-G/W1282X 83 0.87
N2 N1303K/D579G 100 0.66
N2 F508del/3131del15 90 0.50
b2 DeltaF508/D1152H 30 0
N2 F508del/G85E 85 0.67
b2 R117H/R334W 18 0
b2 D1152H/Y849X 16 0
recurrent tract infections, RAP = recurrent abdominal pain, LD = liver disease,
Fig. 2. Correlation between PIP score and chloride sweat level.
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tions is well-representative of CFTR function.
As previously described, a small proportion of PS patients
carrying severe mutations on both alleles may have a high risk to
progressively develop PI [9,11,20,21]. In our cohort of patients 4/
122 (3.2%) with CF severe mutations on both alleles sweat
chloride concentrations over 60 mmol/l and PIP score N0.25
presented ARP; among them one patient experienced ARP
developing PI 6.5 years later the first episode of pancreatitis,
much earlier than data previously reported on risk of PS-PI
progression [11]. So far, we underline that a careful monitoring of
pancreatic function is recommended, especially for those patients
with severe CFTR mutations who experience pancreatitis in
childhood.
On the basis of our preliminary results we suggest that PIP score
should be applied to predict the risk of pancreatitis in children with
CF, from diagnosis. Our findings could promote diagnostic and
therapeutic programs in patients at risk of pancreatitis (PIP b 0.25)
in order to prevent pancreatic disease progression.
As reported by Ooi, the occurrence of mild mutations on
both alleles may confer a significantly higher cumulative
proportion and greater risk of pancreatitis than those with mild/
severe and severe/severe allele combinations [10,11], but we
were not able to verify this association because the follow up of
our patients has been restricted to pediatric population.
Current clinical practices recommend an early detection of
patients at risk of pancreatitis in order to improve their own
lifestyle for preventing recurrence of AP and controlling
progression of pancreatic disease.
Nowadays it is difficult for pediatricians to establish the follow
up of pancreatitis and reassure the families as regards their kid's
future. In these cases, an available standardized score which
predicts the risk of pancreatitis could be a useful tool for clinical
practice.
Despite the small sample size and a shorter follow-up of this
retrospective observational study, our data are in agreement withthose of Ooi. We suggest that PIP score, sufficient pancreatic
status and normal/borderline sweat chloride levels could be
applied in order to predict the risk of developing pancreatitis in
children with CF.
PIP score has potential for other applications also including
predicting PI phenotype and classifying patients with either
severe or mild genotypes irrespective whether, but especially
when, the mutation class is unknown.
We also encourage larger epidemiological studies in order to
validate the role of this score in children with other hereditary
pancreatitis [15,22–24].Conﬂict of interest statement
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